Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection.
Strategies to increase influenza vaccination coverage in the Italian pediatric population: a literature review and expert opinion
Vaccination rates in Italian children must be substantially increased to control the transmission of seasonal influenza and mitigate the associated socio-economic burden.
What COVID-19 taught us about protecting kids in future pandemics
Five years after the World Health Organization declared COVID-19 a global pandemic, infectious disease experts continue to draw on its lessons for future disasters.
Burden of RSV infections among young children in primary care: a prospective cohort study in five European countries (2021–23)
The majority of RSV infections in young children are managed in primary care, however, the disease burden in this setting remains poorly defined.
On the verge of RSV disease prevention: A communications toolkit
Use these materials to raise awareness about new immunisation products to protect infants in early life from a top cause of severe respiratory infections in children.
Temporal Trends in Respiratory Infection Epidemics Among Pediatric Inpatients Throughout the Course of the COVID-19 Pandemic From 2018 to 2023 in Fukushima Prefecture, Japan
Strengthening of nonpharmaceutical interventions changed the epidemic dynamics of pediatric infectious diseases, with a trend toward older hospitalized children.
A 24-month National Cohort Study examining long-term effects of COVID-19 in children and young people
Some children and young people (CYP) infected with SARS-COV-2 experience impairing symptoms post-infection, known as post-COVID-19 condition (PCC).
Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, RSV is now almost a household word. New solutions, such as long-acting monoclonal antibodies and maternal vaccination, both recently recommended by WHO, could dramatically alter the RSV landscape.
